Axel Rüfer
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Zander T, Pabst T, Schär S, Aebi S, Mey U, Novak U, Lerch E, Rhyner Agocs G, Goede J, Maniecka Z, Hayoz S, Rüfer A, Renner C, Driessen C. Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia 2023; 37:699-701.
12.01.2023Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
12.01.2023Leukemia 2023; 37:699-701
Zander Thilo, Pabst Thomas, Schär Sämi, Aebi Stefan, Mey Ulrich J M, Novak Urban, Lerch Erika, Rhyner Agocs Gaëlle, Goede Jeroen, Maniecka Zuzanna, Hayoz Stefanie, Rüfer Axel, Renner Christoph, Driessen Christoph
Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
Rüfer A, Angermann H, Benz R, Bonadies N, Calderoni A, Cantoni N, Efthymiou A, Escher R, Favre G, Friess D, Gschwend A, Himmelmann A, Holbro A, Keller P, Kouroupi E, Lehmann T, Pedarnig N, Rigamonti V, Samii K, Schmidt A, Schäfer H, Sperb R, Stussi G, Winkler A, Zenhäusern R, Goede J. Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q). Hemasphere 2022; 6:e741.
17.06.2022Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q).
17.06.2022Hemasphere 2022; 6:e741
Rüfer Axel, Angermann Hubert, Benz Rudolf, Bonadies Nicolas, Calderoni Antonello, Cantoni Nathan, Efthymiou Anna, Escher Robert, Favre Geneviève, Friess Dorothea, Gschwend Andreas, Himmelmann Andreas, Holbro Andreas, Keller Peter, Kouroupi Eirini, Lehmann Thomas, Pedarnig Nikolaus, Rigamonti Véronique, Samii Kaveh, Schmidt Adrian, Schäfer Hans-Peter, Sperb Roland, Stussi Georg, Winkler Annette, Zenhäusern Reinhard, Goede Jeroen
Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
Driessen C, Pabst T, Hitz F, Hawle H, Rondeau S, Berset C, Besse A, Besse L, Ribi K, Samaras P, Mey U, Rüfer A, Mach N, Betticher D, Cantoni N, Novak U, Müller R, Zander T. Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma. Blood 2018
20.09.2018Promising activity of nelfinavir-bortezomib-dexamethasone (NeVd) in proteasome inhibitor-refractory multiple myeloma
20.09.2018Blood 2018
Driessen Christoph, Pabst Thomas, Hitz Felicitas, Hawle Hanne, Rondeau Stephanie, Berset Catherine, Besse Andrej, Besse Lenka, Ribi Karin, Samaras Panagiotis, Mey Ulrich, Rüfer Axel, Mach Nicolas, Betticher Daniel, Cantoni Nathan, Novak Urban, Müller Rouven, Zander Thilo